140 related articles for article (PubMed ID: 7652764)
21. Correlation of anterior chamber-associated immune deviation with suppression of corneal epithelial rejection in mice.
Yao YF; Inoue Y; Miyazaki D; Hara Y; Shimomura Y; Tano Y; Ohashi Y
Invest Ophthalmol Vis Sci; 1997 Feb; 38(2):292-300. PubMed ID: 9040461
[TBL] [Abstract][Full Text] [Related]
22. Peripheral tolerance via the anterior chamber of the eye: role of B cells in MHC class I and II antigen presentation.
Ashour HM; Niederkorn JY
J Immunol; 2006 May; 176(10):5950-7. PubMed ID: 16670303
[TBL] [Abstract][Full Text] [Related]
23. Ocular immune privilege promoted by the presentation of peptide on tolerogenic B cells in the spleen. II. Evidence for presentation by Qa-1.
D'Orazio TJ; Mayhew E; Niederkorn JY
J Immunol; 2001 Jan; 166(1):26-32. PubMed ID: 11123273
[TBL] [Abstract][Full Text] [Related]
24. Splenic B cells are required for tolerogenic antigen presentation in the induction of anterior chamber-associated immune deviation (ACAID).
D'Orazio TJ; Niederkorn JY
Immunology; 1998 Sep; 95(1):47-55. PubMed ID: 9767456
[TBL] [Abstract][Full Text] [Related]
25. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta.
Wilbanks GA; Mammolenti M; Streilein JW
Eur J Immunol; 1992 Jan; 22(1):165-73. PubMed ID: 1530916
[TBL] [Abstract][Full Text] [Related]
26. Effect of anterior chamber-associated immune deviation (ACAID) on rat islet allograft rejection.
Koevary SB; Beaudry K
Ocul Immunol Inflamm; 2000 Mar; 8(1):39-47. PubMed ID: 10806433
[TBL] [Abstract][Full Text] [Related]
27. Studies on the induction of anterior chamber-associated immune deviation (ACAID). 1. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood.
Wilbanks GA; Streilein JW
J Immunol; 1991 Apr; 146(8):2610-7. PubMed ID: 1707912
[TBL] [Abstract][Full Text] [Related]
28. Genetic restrictions and cellular interactions in the induction of anterior chamber associated immune deviation (ACAID).
Ferguson TA; Kaplan HJ
Reg Immunol; 1988; 1(1):62-8. PubMed ID: 2978943
[TBL] [Abstract][Full Text] [Related]
29. Serum TABM produced during anterior chamber-associated immune deviation passively transfers suppression of delayed-type hypersensitivity to primed mice.
Wang Y; O'Rourke J; Cone RE
Int Immunol; 1997 Feb; 9(2):211-8. PubMed ID: 9040003
[TBL] [Abstract][Full Text] [Related]
30. Blood-borne signals that induce anterior chamber-associated immune deviation after intracameral injection of antigen.
Streilein JW; Okamoto S; Hara Y; Kosiewicz M; Ksander B
Invest Ophthalmol Vis Sci; 1997 Oct; 38(11):2245-54. PubMed ID: 9344347
[TBL] [Abstract][Full Text] [Related]
31. Lymphoma allografts abrogate immune privilege within the anterior chamber of the eye.
Niederkorn JY; Streilein JW
Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1235-43. PubMed ID: 3089965
[TBL] [Abstract][Full Text] [Related]
32. Role of IFN-γ in the establishment of anterior chamber-associated immune deviation (ACAID)-induced CD8+ T regulatory cells.
Paunicka K; Chen PW; Niederkorn JY
J Leukoc Biol; 2012 Mar; 91(3):475-83. PubMed ID: 22180630
[TBL] [Abstract][Full Text] [Related]
33. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction.
Sano Y; Ksander BR; Streilein JW
Invest Ophthalmol Vis Sci; 1995 Oct; 36(11):2176-85. PubMed ID: 7558710
[TBL] [Abstract][Full Text] [Related]
34. Suppression of delayed-type hypersensitivity to third party "bystander" alloantigens by antigen-specific suppressor T cells.
Bianchi AT; Hussaarts-Odijk LM; Benner R
Cell Immunol; 1983 Oct; 81(2):333-44. PubMed ID: 6227391
[TBL] [Abstract][Full Text] [Related]
35. Ocular immune privilege and CD1d-reactive natural killer T cells.
Sonoda KH; Stein-Streilein J
Cornea; 2002 Mar; 21(2 Suppl 1):S33-8. PubMed ID: 11995808
[TBL] [Abstract][Full Text] [Related]
36. Effect of cyclosporine on anterior chamber-associated immune deviation with retinal transplantation.
Ishioka M; Okamoto S; Streilein JW; Jiang LQ
Invest Ophthalmol Vis Sci; 1997 Sep; 38(10):2152-60. PubMed ID: 9331279
[TBL] [Abstract][Full Text] [Related]
37. Role of tumor necrosis factor receptor expression in anterior chamber-associated immune deviation (ACAID) and corneal allograft survival.
Niederkorn JY; Mayhew E; Mellon J; Hegde S
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2674-81. PubMed ID: 15277491
[TBL] [Abstract][Full Text] [Related]
38. Antigen presentation by Langerhans cells in vivo: donor-derived Ia+ Langerhans cells are required for induction of delayed-type hypersensitivity but not for cytotoxic T lymphocyte responses to alloantigens.
Peeler JS; Niederkorn JY
J Immunol; 1986 Jun; 136(12):4362-71. PubMed ID: 3519767
[TBL] [Abstract][Full Text] [Related]
39. Impaired induction of delayed hypersensitivity following anterior chamber inoculation of alloantigens.
Williamson JS; Streilein JW
Reg Immunol; 1988; 1(1):15-23. PubMed ID: 2978942
[TBL] [Abstract][Full Text] [Related]
40. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses.
Niederkorn JY; Streilein JW
J Immunol; 1983 Dec; 131(6):2670-4. PubMed ID: 6196396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
